Repair of 3-methyladenine and abasic sites by base excision repair mediates glioblastoma resistance to temozolomide

Abstract excerpt

Alkylating agents have long played a central role in the adjuvant therapy of glioblastoma (GBM). More recently, inclusion of temozolomide (TMZ), an orally administered methylating agent with low systemic toxicity, during and after radiotherapy has markedly improved survival. Extensive in vitro and in vivo evidence has shown that TMZ-induced O(6)-methylguanine (O(6)-meG) mediates GBM cell killing. Moreover, low or...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Brain Metastases and Treatment
• Share to DNA Repair Mechanisms
• Share to Glioma Diagnosis and Treatment